Vir Biotechnology Long Term Debt

Vir Biotechnology's long-term debt stands at $87M as of March 2026. That compares with $88M in the prior-year period — down 1.7% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Vir Biotechnology reported $87M in long-term debt versus $88M a year earlier — a 1.7% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $88M in the prior-year period — down 1.7% year over year. Sustained growth in long-term debt can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Vir Biotechnology's long-term debt evolved across reporting periods, while the comparison chart places VIR next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, long-term debt is commonly used to spot outliers. Vir Biotechnology's reading of $87M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.